GSK
R&D/ Views & Analysis/ Views and analysis
US vs EU: How can Europe translate home-grown innovation into biotech success?
Amanda Barrell
BioNTech, Biotech, EU, GSK, Pfizer, Roche, The European Commission
0 Comment
R&D/ Views & Analysis/ Views and analysis
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
mike.hammerton@pharmaphorum.com
Biogen, GSK, Merck, Q4 2021, quarterly results
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis
GSK’s Neale Belson on building trust with employees and society
George Underwood
climate change, GSK, reputation, Sustainability, UK Leaders
0 Comment
Podcast/ R&D/ Views & Analysis/ Views and analysis
GSK and eosinophil research: the pharmaphorum podcast
Digital/ Market Access/ R&D/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
Pharma’s response to COVID: GSK
mike.hammerton@pharmaphorum.com
COVID-19, GSK, Pharma’s Response to COVID-19
0 Comment
Market Access/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
A history of the pharmaceutical industry
Rebecca
A history of..., Aspirin, Bayer, Eli Lilly, GSK, History of the pharmaceutical industry, insulin, Merck, NHS, penicillin, Pfizer, Sandoz, Wyeth
0 Comment
Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution
FDA approves GSK’s Blenrep for advanced multiple myeloma
Richard Staines
Blenrep, cancer, GSK, multiple myeloma
0 Comment